Related Experiment Videos
Sintered dicalcium pyrophosphate increases bone mass in ovariectomized rats
Jui-Sheng Sun1, Yi-Chau Huang, Yang-Hwei Tsuang
1Department of Orthopedic Surgery, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, Taiwan, Republic of China.
Journal of Biomedical Materials Research
|December 18, 2001
Summary
Sintered dicalcium pyrophosphate, a synthetic pyrophosphate analog, shows promise for treating osteoporosis. This study found it increased bone mass and mineral content in ovariectomized rats without harming organs.
Area of Science:
- Biochemistry
- Pharmacology
- Orthopedics
Background:
- Osteoporosis is a significant health concern, often treated with bisphosphonates.
- Sintered dicalcium pyrophosphate (DCP) is a pyrophosphate analog with potential therapeutic applications for bone loss.
Purpose of the Study:
- To evaluate the efficacy of orally administered sintered DCP in an ovariectomized rat model of osteoporosis.
- To assess the impact of sintered DCP on bone mass, bone mineral content, and bone histology.
Main Methods:
- Ovariectomized rats were randomly assigned to control groups or treatment groups receiving alendronate sodium or varying doses of sintered DCP.
- Bone mass, bone mineral content, and visceral organ histology were analyzed after a 4-week treatment period.
Main Results:
- Sintered DCP ingestion did not cause adverse effects on major visceral organs.
- Both alendronate sodium and sintered DCP treatment led to decreased bone porosity and increased bone mineral content in the long bones of ovariectomized rats.
Conclusions:
- Sintered dicalcium pyrophosphate effectively increases bone mass in an ovariectomized rat model.
- Sintered DCP represents a potential therapeutic agent for managing osteoporosis and preventing bone loss.